Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.69 |
| ▸ | PI4KA | P42356 | 2/20 | 0.69 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.69 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.69 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.69 |
| ▸ | DPP4 | P27487 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.69 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.69 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.69 |
| ▸ | GAPDH | P04406 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.69 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.69 |
| ▸ | STAT6 | P42226 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.69 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28680450 | 1.00 | ADORA1 (0.72) | ADORA1ADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL1060588 | 1.00 | ADORA1 (0.72) | ADORA1ADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL26370816 | 1.00 | ADORA1 (0.72) | ADORA1ADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL1060584 | 1.00 | ADORA1 (0.72) | ADORA1ADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL21999787 | 0.92 | ADORA1 (0.61) | ADORA1ADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL25966341 | 0.92 | ADORA1 (0.61) | ADORA1ADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL31139492 | 0.92 | ADORA3 (0.69) | ADORA1ADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL5220374 | 0.92 | ADORA3 (0.69) | ADORA1ADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL5220384 | 0.92 | ADORA3 (0.69) | ADORA1ADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL29750660 | 0.91 | ADORA1 (0.68) | ADORA1ADORA3PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026097135-A1 | RIG-I INHIBITORS | Pharmorage Pty Limited (AU) | 2026-05-15 | — | — | WO | claimed |
| CN-117321206-A | IL-34 antisense agents and methods of use thereof | 诺格拉制药有限公司 | 2023-12-29 | — | — | CN | claimed |
| CN-114729363-A | IL-34 antisense agents and methods of use thereof | 诺格拉制药有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-122095094-A | Compositions targeting KLKB1 and methods of use thereof | — | 2026-05-26 | — | — | CN | disclosed |
| WO-2026097135-A1 | RIG-I INHIBITORS | Pharmorage Pty Limited (AU) | 2026-05-15 | — | — | WO | disclosed |
| WO-2026102260-A1 | CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING ANGIOPOIETIN LIKE 3 (ANGPTL3) | EDITAS MEDICINE, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| CN-122036831-A | Oligonucleotide purification method | 上海奥锐特生物科技有限公司 | 2026-05-15 | — | — | CN | disclosed |
| WO-2026101913-A1 | SIRNAS TARGETING COMPLEMENT FACTOR H-RELATED (CFHR) GENE TRANSCRIPTS AND METHODS OF USE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4727929-A2 | 5'-MODIFIED MONOMERS, OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS | Alnylam Pharmaceuticals, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260103714-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | CONTERA PHARMA AS (DK) | 2026-04-16 | — | — | US | disclosed |
| EP-3458464-B1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHOROTHIOATE OLIGORIBONUCLEOTIDES | ETH ZUERICH (CH) | 2026-04-15 | — | — | EP | disclosed |
| WO-2022087041-A1 | METHODS AND COMPOSITIONS FOR TREATING PRIMARY HYPEROXALURIA | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| EP-3987030-A2 | PPM1A INHIBITORS AND METHODS OF USING SAME | Quralis Corporation (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-114375194-A | Treatment of angiopoietin-like 7(ANGPTL7) -related diseases | 艾姆皮瑞克公司 | 2022-04-19 | — | — | CN | disclosed |
| WO-2022072356-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANGIOPOIETIN LIKE 7 (ANGPTL7) RELATED DISEASES | EMPIRICO INC. (US) | 2022-04-07 | — | — | WO | disclosed |
| WO-2022056127-A9 | IRNA COMPOSITIONS AND METHODS FOR SILENCING GROWTH FACTOR RECEPTOR BOUND PROTEIN 10 (GRB10) OR GROWTH FACTOR RECEPTOR BOUND PROTEIN 14 (GRB14) IN THE LIVER | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
| EP-3976059-A2 | TREATMENT OF ANGIOPOIETIN LIKE 7 (ANGPTL7) RELATED DISEASES | EMPIRICO INC. (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-107690480-B | Evaluation of CAS9 molecule/guide RNA molecule complexes | 爱迪塔斯医药公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-108368507-B | iRNA compositions of programmed cell death 1 ligand 1(PD-L1) and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2022-03-22 | — | — | CN | disclosed |
| WO-2022056127-A2 | IRNA COMPOSITIONS AND METHODS FOR SILENCING GROWTH FACTOR RECEPTOR BOUND PROTEIN 10 (GRB10) OR GROWTH FACTOR RECEPTOR BOUND PROTEIN 14 (GRB14) IN THE LIVER | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103714-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | NAT10, NAT1, NAA40 | ADORA1 1286/4885ADORA3 1427/4885PI4KA 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.